Navigation Links
Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering
Date:1/15/2014

LAWRENCEVILLE, N.J., Jan. 15, 2014 /PRNewswire/ -- Celsion Corporation (the "Company") (NASDAQ: CLSN) today announced that it has received commitments from institutional investors to purchase an aggregate of approximately $15 million of the Company's common stock in an at-the-market registered direct offering, led by a dedicated health care fund.

The Company entered into definitive purchase agreements with these investors pursuant to which the Company agreed to sell an aggregate of 3,603,603 shares of its common stock at a per share price of $4.1625.  Additionally, for each share of common stock purchased, investors will receive a Series A Warrant to purchase one-quarter of a share of our common stock at an exercise price of $4.10 per share, which shall be exercisable immediately and expire five years from the date of issuance, and a Series B Warrant to purchase one-quarter of a share of our common stock at an exercise price of $4.10 per share, which shall be exercisable immediately and expire one year from the date of issuance. The closing of the offering is expected to take place on or about January 21, 2014, subject to the satisfaction of customary closing conditions.

The estimated net proceeds to the Company from the offering are expected to be approximately $13.8 million.  With the net proceeds from this offering, the Company projects to have an unaudited cash and investment balance of approximately $57 million.  The Company intends to use the net proceeds from this offering for general corporate purposes.

H.C. Wainwright & Co., LLC  acted as exclusive placement agent in connection with the offering.

A shelf registration statement (File No. 333-183286) relating to the shares issued in the offering has been filed with and declared effective by the Securities and Exchange Commission (the "SEC"
'/>"/>

SOURCE Celsion Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials at the 2013 San Antonio Breast Cancer Conference
2. Celsion Corporation Announces Strategic Loan Facility
3. Celsion Corporation Reports Third Quarter 2013 Financial Results and Provides Business Update
4. Celsion Corporation to Hold Third Quarter 2013 Financial Results Conference Call on Tuesday, November 12, 2013
5. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials to be Presented at the 2013 San Antonio Breast Cancer Conference
6. Celsion Corporation Reports Second Quarter 2013 Financial Results and Provides HEAT Study Update
7. Celsion Corporation to Hold Second Quarter 2013 Financial Results Conference Call on Thursday, August 8, 2013
8. Celsion Corporation Issues Statement Regarding Misleading Blog Entry
9. Celsion Corporation Reports Year End 2012 Financial Results and Provides Business Update
10. Celsion Corporation to Hold Year-End 2012 Financial Results Conference Call On Monday, March 18, 2013
11. Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... -- ABIVAX, a clinical stage biotech company developing ... it has dosed in New Zealand ... ABX203 which is taking place in several countries of the ... to assess whether ABX203 can deliver a significant improvement in ... load for a much longer period of time when compared ...
(Date:2/26/2015)... Medtronic, Inc. (U.S.), St. Jude Medical, ... in the Saudi Arabia , ... expected to lead the market during the period of 2014 ... player in the market, and owns a wide product portfolio ... Entera Neurostimulator are some of the most popular brands of ...
(Date:2/26/2015)... --  HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter ended December 31, 2014, a 38% ... same period of 2013.  For the fiscal year 2014, ... increase compared to revenue of $207.9 million in 2013.  ...
Breaking Medicine Technology:ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 2ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 3ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 4ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 5Middle East & Africa Internal Neurostimulation/Neuromodulation Market is Expected to Reach $6.1 Million by 2019, at a CAGR of 17.9% from 2014 to 2019 2Middle East & Africa Internal Neurostimulation/Neuromodulation Market is Expected to Reach $6.1 Million by 2019, at a CAGR of 17.9% from 2014 to 2019 3Middle East & Africa Internal Neurostimulation/Neuromodulation Market is Expected to Reach $6.1 Million by 2019, at a CAGR of 17.9% from 2014 to 2019 4HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 2HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 3HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 4HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 5HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 6HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 7HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 8HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 9HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 10HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 11HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 12
... (OTCQB: ABHI), a leader in the development of wireless products ... a new line of credit with East West Bank, renewing ... July 2011. The new line of credit expands AmbiCom,s available ... revolving line and extends the line by one year to ...
... N.J., May 24, 2011 Systech International®, innovator ... our Brazilian Partner Videojet today announced that one ... to implement Systech,s Serialized Product Tracking (SPT) ... in Brazil.  The manufacturer will employ Systech SPT ...
Cached Medicine Technology:AmbiCom Renews and Expands Line of Credit With East West Bank 2AmbiCom Renews and Expands Line of Credit With East West Bank 3Top Pharmaceutical Manufacturer Selects Systech to Meet Brazil's Anti-Counterfeiting Regulatory Requirements 2Top Pharmaceutical Manufacturer Selects Systech to Meet Brazil's Anti-Counterfeiting Regulatory Requirements 3Top Pharmaceutical Manufacturer Selects Systech to Meet Brazil's Anti-Counterfeiting Regulatory Requirements 4
(Date:2/26/2015)... As the great passage beyond midlife gathers ... more substantial roles and connections that span the generations ... a life that still matters? As The Aspen Club ... Year Total Immersion Retreat , answers to these types ... and jump-starts a healthier life. A new round of ...
(Date:2/26/2015)... Imagine a day without access to clean, drinkable water ... was no one to help. For more than 783 million ... more than 2.5 billion people will also lack access to ... initiative led by Nevada’s Desert Research Institute (DRI) ... women – who often bear the brunt of the impact ...
(Date:2/26/2015)... NY (PRWEB) February 26, 2015 The ... with Topical BioMedics, Inc., Rhinebeck, NY, to offer customers ... creams—patented topical biomedicine formulas that safely and effectively address ... a new division of Vets Access LLC, Montrose, MI, ... and healing products. , Topical BioMedics is a research ...
(Date:2/26/2015)... Scotch Plains, NJ (PRWEB) February 26, 2015 ... celebrating the reopening of their newly renovated office in ... Mann, the Reproductive Science Center of New Jersey’s physicians, ... outstanding work and patient care in the areas of ... is commended for having excellent success rates and providing ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 Beckman Coulter ... of extracellular vesicles and their cargo in cell-to-cell communication,” ... and their relevance for cell-to-cell communication. The webinar is ... 4, 2015 at 8:00am PT. , Every cell in ... vesicles (EVs) , often called “exosomes” or “microvesicles.” These ...
Breaking Medicine News(10 mins):Health News:The Aspen Club on Actively Aging: Telling a New Story on Aging 2Health News:DRI launches Global Initiative to Provide Women in Developing Countries with Clean Water 2Health News:DRI launches Global Initiative to Provide Women in Developing Countries with Clean Water 3Health News:COR HEALTH Division of Vets Access Partners with Topical BioMedics to Provide Natural Pain Relief Products 2Health News:COR HEALTH Division of Vets Access Partners with Topical BioMedics to Provide Natural Pain Relief Products 3Health News:RSCNJ Is Celebrating the Reopening of Their Newly Renovated Office 2Health News:RSCNJ Is Celebrating the Reopening of Their Newly Renovated Office 3Health News:Beckman Coulter Webinar Series Presents Diversity of Extracellular Vesicles and Their Cargo in Cell-to-cell Communication 2Health News:Beckman Coulter Webinar Series Presents Diversity of Extracellular Vesicles and Their Cargo in Cell-to-cell Communication 3
... release are posted on the Mayo,Clinic News Blog: http://newsblog.mayoclinic.org/ ... for TV broadcast upon request., ROCHESTER, Minn. July 31 ... both men and women. For men,the record pace for the ... the 10,000-meter run just after World War II. Today, champion ...
... "open access" or free online, they get read more ... -- get cited more often in academic literature, finds ... student Philip Davis and colleagues, including three Cornell professors, ... access they need to relevant articles. , "It appears ...
... (Nasdaq:,EVVV) today announced that Pat Spangler, chief financial officer, ... at the,Canaccord Adams 28th Annual Global Growth Conference on ... Canaccord Adams 28th Annual Global,Growth Conference will be held ... the webcast, go to the investors, section of the ...
... 31 Halozyme Therapeutics,Inc. (Nasdaq: HALO ), ... extracellular matrix, today,announced that it will release financial ... 30, 2008 before market open on Friday, August ... Chief Executive Officer, Gregory Frost,PhD, Vice President and ...
... of Michigan to spray the state,s apple orchards with ... to treat blood infections in newborns and other serious ... America (IDSA). , The Environmental Protection Agency (EPA) ... to use gentamicin to fight a tree disease called ...
... Stereotaxis, Inc. (Nasdaq:,STXS) announced today that it ... ended June 30, 2008, on Tuesday, August 5, ... a conference call and webcast on,Tuesday, August 5, ... the Company,s,second quarter results and current corporate developments. ...
Cached Medicine News:Health News:Mayo Clinic on the Summer Olympic Games: Better Athletes, the Physiology of Performance, the Lactate Threshold, the Aging Athlete and Much More 2Health News:Mayo Clinic on the Summer Olympic Games: Better Athletes, the Physiology of Performance, the Lactate Threshold, the Aging Athlete and Much More 3Health News:Mayo Clinic on the Summer Olympic Games: Better Athletes, the Physiology of Performance, the Lactate Threshold, the Aging Athlete and Much More 4Health News:Mayo Clinic on the Summer Olympic Games: Better Athletes, the Physiology of Performance, the Lactate Threshold, the Aging Athlete and Much More 5Health News:Mayo Clinic on the Summer Olympic Games: Better Athletes, the Physiology of Performance, the Lactate Threshold, the Aging Athlete and Much More 6Health News:Mayo Clinic on the Summer Olympic Games: Better Athletes, the Physiology of Performance, the Lactate Threshold, the Aging Athlete and Much More 7Health News:Free articles get read but don't generate more citations 2Health News:Halozyme Therapeutics to Hold Pipeline Update Conference Call on August 8 2Health News:Physicians ask EPA, 'Antibiotics to cure sick apples, or sick children?' 2
... Graham-Field has been developing diverse ... 58 years. Our medical-surgical products ... for innovation, quality and customer ... include the Labtron® line of ...
... medication nebulizers offer a spill-proof design and ... a 45° angle. All medical nebulizers are ... variety of configurations are available., ,All ... ,Portex® medication nebulizers feature consistently fine ...
... Hand Held Nebulizer can be held at angles ... has a built in spill column, finger grooves ... medication setups and 7 feet of regular oxygen ... maintain small particle size and sustain optimum mist ...
... Anesthesia and Respiratory Products, ,Westmed designs, ... for Anesthesia and Respiratory professionals. Our mission ... enhance the clinician's ability to deliver quality ... the bottom line. , ,Our web ...
Medicine Products: